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1. Introduction
Prostate cancer is the most commonly diagnosed cancer in men and the second leading
cause of cancer related mortality. Localized prostate cancer is treated by either radical pros‐
tatectomy or radiotherapy. Low levels of testosterone have been associated with prostate
cancer progression. These tumor presented advanced tumor stage, high Gleason scores, and
had significantly worse overall survival rate [1, 2]. Indeed, intraprostatic dihydrotestoster‐
one (DHT) were consistently reduced in patients with high-grade (Gleason scores of 7 to 10)
compared to patients diagnosed with low grade tumors (Gleason scores of 6 or less) [3].
Prostate cancer usually is treated using chemotherapy, radiotherapy, or surgery. For ad‐
vanced prostate cancer, hormonal therapy is currently used as the standard treatment, how‐
ever; these tumors develop and aggressive phenotype and become hormone–independent
(hormone-refractory) (HRPC) that is resistant to chemotherapy or radiotherapy and meta‐
stasizes to lymph nodes and bone [4].
Although prostate cancer is the most common cancer in Caucasians, the risk factors associat‐
ed with increased prostate cancer incidences include mainly in those individuals with sub-
Saharan African ancestry, with African-American men having the highest reported
incidence rates of all ethnic groups in the United States (239.8 cases/100,000) [5, 6]. Further‐
more, mortality from prostate cancer following surgery is nearly two-fold higher in African-
American men (56.3/100,000) succumbing to the disease compared to white men
(23.9/100,000) [7-9]. Little is currently know whether the type of factors (biological, diet, ra‐
cial, or lifestyle) that may play a influence role in the increased prostate cancer incidence in
this population. The high mortality in death from prostate cancer is generally due to meta‐
static disease that results from resistance to the treatments described above. Since rates of
prostate cancer in the U.S. are 60 percent higher among African-American men, and their
mortality rate are two-and-a-half times that of Caucasian men [10, 11], identifying the mech‐
anisms that support indolent against aggressive disease is an important area of research.
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Prostate cancer cells that survive chemotherapy or radiation treatment clearly indicate that
may be able to repair most of the radiation-induced DNA breaks. Indeed, different prostate
cancer cell lines have shown a very efficient DNA repair system in which DNA damage can
be removed [4, 12]. Also, there is the possibility that genetic instability occurring in those
cancer cells with unrepaired or misrepaired DNA damage might increase prostate cancer
aggressiveness. In this regard, there is an increasing interest in the utilization of PARP inhib‐
itors as a strategy for improving cancer therapy [13]. PARP is a nuclear enzyme that plays
active roles in DNA repair, DNA replication, and cell death, in response to diverse forms of
stimuli from normal metabolic processes, as well as environmental factors [14, 15]. This en‐
zyme binds nonspecifically to DNA breaks and catalyzes the poly(ADP-ribosyl)ation of var‐
ious nuclear proteins utilizing NAD+ as a substrate, leading to chromatin decondensation
that allows the repair process for DNA damage.
Overexpression of PAPR1 has been described in a variety of tumor cell lines, which was as‐
sociated with malignant progression [16]. PARP-1 high levels has also been found in malig‐
nant lymphoma cells compared to normal lymph nodes [16], adjacent non-tumor tissues, or
hyperplastic polyps [17]. High levels of PARP-1 also showed high correlation with poor
prognosis in early breast cancer. In this type of cancer, PARP-1 was indicated to be the major
component of tumor cells response to DNA damage and a key player in maintaining their
genetic stability. Augmented expression of PARP-1 was also observed in moderate differen‐
tiate hepatocellular carcinomas (HCC) [18]. In addition, poly(ADP-ribosyl)ation was consis‐
tently increased in HCC [19], colon carcinomas [20], cervical cancer [21], and melanoma and
basal cell carcinoma [22]. More recent findings have found that overexpression of PARP-1
appear to be related with prostate cancer progression, and also considered as a potential in‐
dependent predictor of aggressiveness among the clinicopathological features related to this
type of tumor [23].
Prostate tumors that initially respond to standard chemotherapy often recur; with selective
outgrowth of tumor cell subpopulations that are resistant not only to the original chemo‐
therapeutic agent, but also to other therapeutics. Therefore, the promising results of PARP
inhibitors in treating advanced states of prostate cancer provide new avenues for effective
treatment of this deadly disease. This chapter focuses on PARP-1 as a potential target to im‐
prove the breadth and effectiveness of prostate cancer treatment.
2. The biological roles of PARP-1
PARP-1 is a nuclear protein that catalyzes the covalent long chain poly(ADP-ribosyl)ation of
a variety of nuclear proteins utilizing β-nicotinamide adenine dinucleotide (NAD+) as a sub‐
strate, with PARP-1 itself being the major target of modifications [24, 25]. Moreover, many
other nuclear DNA binding proteins are also modified. PARP-1 is only activated when
bound to single- or double-stranded DNA ends via its two zinc fingers, which recognize
DNA breaks independent of the DNA sequence [14, 15, 25] (Table 1). The active protein cat‐
alyzes a sequential transfer reaction of ADP-ribose units from NAD+ to various nuclear pro‐
teins, forming a protein-bound polymer of ADP-ribose units [24].
Advances in Prostate Cancer592
Agents that activatePARP-1 Events inducing DNA breaks
Alkilating agents Aging
Apoptosis inducers Chromosomal alterations
Asbestos Differentiation
Hydrogen peroxide (H2O2) Gene expression
Ionizing radiation Genetic instability
Oxidising agents DNA replication
Nitrosative stress Inflammation
Topoisomerase inhibitors Necrosis
Programming cell death
Table 1. List of events that promote DNA breaks and PARP-1 activation
Since PARP-1 activation is strictly proportional to the number of DNA breaks, its activity is
strictly proportional to the number of DNA breaks in vivo or in vitro, and it is particularly
inactive in the absence of DNA breaks [15, 25, 26]. DNA damage can occur during DNA rep‐
lication or as consequence of exposure of cells to different types of genotoxic agents (Table
1). One of the earliest cellular events that follow this phenomenon is the poly(ADP-ribo‐
syl)ation of PARP-1 and an array of DNA binding proteins that are localized predominantly
adjacent to the DNA strand breaks, resulting in polymers adjacent to DNA breaks and in the
recruitment of additional proteins that are essential in BER/SSBR [27, 28].The covalent
poly(ADP-ribosyl)ation of nuclear DNA-binding proteins in eukaryotes is a phenomena that
contributes to various physiologic and pathophysiologic events associated with DNA strand
breakage, repair of DNA damage, and apoptosis [15, 29-32]. Detailed studies have demon‐
strated that in addition to its accessory role in DNA repair, PARP-1 also plays regulatory
roles in other nuclear processes, including DNA replication and the regulation of transcrip‐
tion, as a longevity assurance factor associated with genome stability, and in redox signaling
[26] (Table 2). In addition, the post-translational modifications reaction in which poly(ADP-
ribosyl)ation is involved during post-translational reactions is mainly related to the modula‐
tion of chromatin and function in DNA-damaged and apoptotic cells [32, 33]. The nuclear
protein substrates of PARP-1 include histones, DNA topoisomerases I and II [34, 35], SV40
large T antigen [36], DNA polymerases α and δ, proliferating cell nuclear antigen (PCNA),
and several proteins that are components of the DNA synthesome [35].
The interaction of PARP-1 with components of the base excision repair (BER) complex such
as DNA ligase III, DNA pol β, and XRCC1 [37-40], suggested that PARP-1 may have protec‐
tive function in the BER repair process. PARP-1 has also been shown to interact with a num‐
ber of transcription factors (Table 3), including AP-2 [41], CXC ligand [41], E2F-1 [32], NF-κB
[42], MYB [43], Oct-1 [44], PC3/topoisomerase-I [45], SP-1, TEF-1 [46], and YY1 [47]. Al‐
though ADP-ribosylation has been indicated as the main mechanism by which PARP-1
modulates most of these transcription factors, consistent reports in which PARP-1 inhibitors
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and the downstream effects of NF-κB pathways were analyzed [48] have argued against the
requirement of PARP-1 as a critical co-activator of NF-κB [49, 50].
Roles of PARP in cellular and molecular processes
Control of cell cycle
Cell differentiation
Cell death
Chromatin architecture
DNA repair
Redox signaling
Transcription
Transformation
Table 2. List of the roles PARP-1 plays in molecular and cellular processes.
The dual roles of PARP-1 in different nuclear processes are based in on the levels of the sub‐
strate NAD+ and the presence of PARP-activating DNA breaks. Indeed, physical interaction
of PARP-1 with DNA polymerase α occurs in the absence of NAD+ activates polymerase α
[51], while addition of NAD+ to the DNA replication complex inhibits polymerase α catalytic
activity [52]. Although in the absence of NAD+, PARP-1 interacts with different transcription
factors to enhance activator-dependent transcription, the presence of NAD+ and consequent
PARP-1 activation represses transcription, presumably by poly(ADP-ribosyl)ation of a series
of transcription factors [53]. Thus for example, in the absence of NAD, PARP-1 enhances ac‐
tivator-dependent transcription by interacting with RNA polymerase II-associated factors
[53], binds to the transcription enhancer factor 1 (TEF1) and enhances muscle-specific gene
transcription [46], and transcription factor AP-2 to co-activate AP-2-mediated transcription
[41]. Meanwhile, PARP-1 depletion silences the activation of a number of transcription fac‐
tors, preventing the formation of active transcription complexes and binding to their respec‐
tive DNA consensus sequences [54].
In most of the cases, the poly(ADP-ribosyl)ation modification of proteins inhibits their affin‐
ity for DNA-binding as a result of the electrostatic repulsion between the negatively charged
DNA and long chain of approximately 200 units of poly(ADP-ribose) (PAR) [24, 25]. Al‐
though unmodified PARP-1 binds tightly to DNA ends, interfering with the repair machi‐
nery, the prolonged poly(ADP-ribosyl)ation automodification of PARP-1 itself is essential to
modulate its binding to DNA ends during the repair process [55, 56]. The decrease in DNA-
binding affinity caused by electrostatic repulsion between DNA and poly(ADP-ribose)
(PAR) as a result of the pos-translational modification may explain the reduction on the cat‐
alytic activity of some DNA-binding proteins [57, 58]. Modification of other nuclear proteins
such as nucleosomal proteins may also allow the access of various replicative and repair en‐
zymes that bind specifically to those regions of the DNA containing strand breaks [59, 60].
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Function Acceptor proteins
Cell cycle regulation p53
PCNA
Chromatin structure Histone
HGM
Lamins
LMG proteins
DNA metabolism DNA polymerase α
DNA polymerase β
DNAS1L3
Endonuclease
PARP-1
Poly(ADP-ribose) synthetase
Topoisomerase I
Topoisomerase II
XRCC1
Others Tankyrase-1
Telomeric repeat binding factor-1
Table 3. List of acceptor proteins for poly(DP-ribose).
The elevated levels of sister chromatid exchanges (SCE) found in PARP-1 knockout mice
have been associated with increased genomic instability [61, 62]. Similar events have been
reported in splenocytes and fibroblasts isolated from PARP-1-/- animals, which also exhibit‐
ed signaling abnormalities, apoptosis, proliferation, and defects in DNA repair [62, 63]. Ac‐
cordingly, animals carrying deletion of the exon 1 [64], exon 2 [61], and exon 4 [62], neither
evidenced PARP-1 protein nor exhibited signals of poly(ADP-ribosyl)ation. It was also de‐
scribed that thymocytes derived from PARP-1 knockout mice showed a delayed recovery af‐
ter exposure to gamma-radiation [61]. Also, PARP-1 inhibition/deletion does not alter key
cellular events such as apoptosis, DNA replication, and differentiation in cells derived from
these mice; however, some evidence has indicated that PARP-1 has supportive roles in all
these processes. Indeed, derived PARP-1 deficient cells showed pronounced effects on some
of these events that are not observed in wild type cells [65, 66].
3. Involvement of PARP-1 in prostate cancer progression
Localized prostate tumors are treated by either radical prostatectomy or radiotherapy and
usually survive many years [67]. For aggressive prostate cancer, hormonal therapy is the
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standard treatment however; a significant amount (approximately 30%) of these tumors be‐
come hormone–independent (hormone-refractory) [11]. Prostate cancer cells that survive
chemotherapy or radiation treatment may be capable to repair most radiation-induced DNA
breaks. This is supported by evidence showing both in androgen dependent and independ‐
ent prostate cancer cell lines in which the EGFR-ERK signaling pathway up-regulates a ser‐
ies of DNA repair proteins, including ERCC1, XPC, and XRCC1, in response to DNA
damage [68]. These proteins efficiently repaired the damaged DNA, and enhanced the sur‐
vival of cells following exposure to genotoxics [68, 69]. The activation of PARP-1 in the pres‐
ence of DNA breaks consistently promotes the recruitment of XRCC1 and the physical
interaction of XRCC1 with PARP-1 has been indicated as an efficient process to repair DNA
breaks in a coordinated manner [39]. However, it needs to be taken into account that genetic
instability may occur in those cells with unrepaired or misrepaired DNA damage. In this re‐
spect, the LNCaP prostate cancer cell line, an androgen-responsive is a good model because
undergoes growth arrest, but not apoptosis after androgen deprivation, and it is also highly
resistant to radiation-induced cell death [70, 71].
Given that activation of PARP-1 is absolutely dependent on DNA strand breaks [15, 26], the
substantial poly(ADP-ribosyl)ation modification of PARP-1 detected during early apoptosis
in LNCaP cells was consistent with the DNA damage induced by Phenoxodiol, a synthetic
analogue of Genistein [72]. Although the level of PARP-1 activation and its subsequent
cleavage in LNCaP cells after Phenoxodiol exposure was exhibited in a time dependent
manner, the poly(ADP-ribosyl)ation automodification of PARP-1 activation during the early
stages of Phenoxodiol-induced apoptosis may thus be required for progression through the
death program [72]. In this respect, subsequent cleavage of PARP-1 may have prevented the
depletion of NAD+ and ATP, which are needed for later steps in apoptosis [73]. However,
the possibility that inhibition of the topoisomerase II activity may have caused DNA dam‐
age in cells exposed to Phenoxodiol, a well-known topoisomerase II poison, was not exclud‐
ed [74]. As a matter of fact, activation of PARP-1 has also been detected in apoptotic cells
exposed to different antineoplastic agents, such as adriamycin, alkylating agents, cisplatin,
mitomycin C, radiation, and topoisomerase inhibitors [75].
A combined treatment of isoflavones and curcumin had a potent inhibitory effect on cellular
proliferation of LNCaP cells [76]. The effects associated with this treatment were the en‐
hanced phosphorylation of some nuclear proteins, such as ATM and Chk2 when compared
to the effects of cells treated with curcumin alone. Similar effects were observed in the his‐
tone H2AX and p53. Interesting, curcumin also inhibited the proliferative effects of the dihy‐
drotestosterone (DHT), a stimulator of prostate growth [3]. The augmented levels of
testosterone consistently induced activation of the DNA damage response (DDR) pathways
in response to curcumin treatment by promoting the phosphorylation of CHK, H2AX and
p53. This approach also induced the proteolytic cleavage of PARP-1, suggesting that activa‐
tion of the DDR by polyphenols might have a suppress effect on malignant transformation,
while a combined therapy of testosterone and curcumin may enhances apoptosis by pro‐
moting the release of pro-apoptotic factors, restricting thus prostate cancer progression.
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To determine the signaling pathways that are induced by radiation-induced PARP-1 activa‐
tion, two prostate cancer cell lines LNCaP and DU145, which express different levels of
EGFR, were exposed to ionizing radiation and EGF [77]. Although the radiosensitivity was
much more evident in LNCaP cells, the radiation treatment consistently reduced the clono‐
genic survival in both cell lines. The addition of EFG or PD184352, a MEK 1/2 inhibitor, had
any significant impact on the killing of the cancer prostate cells. In contrast, PJ34, a potent
inhibitor of PARP-1 [78], caused a growth arrest and markedly reduced cell death in both
cell lines [77]. In support of these data, poly ADP-ribosylation of PARP-1 was also evident in
LNCaP and DU145 cells after irradiation or exposure to EGF. These results are supported by
findings linking EGF expression to human prostate cancer development [79, 80], the high
levels of EGF secreted by LNCaP and DU145 cell lines [81, 82], as well as the enhanced inva‐
sive capacity that EGF exert on another human prostate cancer cell line (PC-3) [83]. Al‐
though the reduction of cell death was evident in cells exposed to PJ34 and EGF; however,
an opposite effect was observed when PD184352 or the inhibitor of EGF receptor kinase,
AG1478, alone was added to the cultures. When the same experimental approaches were ap‐
plied to PARP-1-depleted cells, expression of poly ADP-ribose production was practically
eliminated [78]. This study indicated that PARP-1 activation in both cell lines is linked to the
EGF-ERK signaling pathway, which may be critical for the poly ADP-ribosylation and regu‐
lation of NAD+ content following irradiation, and may also be critical for cell survival after
treatment for prostate cancer.
Similar apoptotic effects including, annexin-V binding and TUNEL staining, loss of mito‐
chondrial membrane potential the release of cytochrome c, activation of caspase-3, and in‐
crease of PARP-1 cleavage were observed in PC-3 cells treated with b-caryophyllene oxide
(CPO), wortmannin, and the AKT inhibitor IV [84]. Downregulation of several proteins that
are part of the PI3K/AKT/mTOR/S6K1 signaling cascade and ROS-mediate MAPKs activa‐
tion were also identified, which strongly suggested that multiple cascades are involved in
cell survival and proliferation of prostate cancer cells. Accordingly, LNCaP cells exposed to
isochaihulactone, a lignin with proved antitumor activity in vitro and in vivo models [85],
evidenced the involvement of the JNK pathway as a potential target for the activation of
proteases that are crucial in the induction of caspase-3 activation and PARP-1 cleavage, hall‐
marks of apoptosis cell death.
4. The relationship between the expression of PARP-1 and p53 in prostate
cancer
It is well known that the tumor suppressor gene p53 is a key player in controlling the genet‐
ic stability in breast tumor cells [86]. More recently, it was reported that inhibition of
PARP-1 by veliparib enhances DNA damage in BRCA-proficient cancer cells, a process that
appears to be regulated by p53. Although a diverse response was observed in p53-mutant or
–null cells, the veliparib and topotecan combination enhanced DNA damage response and
cell death in these type of cells [87]. Similarly, treatment of LNCaP cells to a new ligan iso‐
chaihulactone, a proved inhibitor of cell proliferation and effective inducer of apoptosis in a
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variety of cancer cell lines, enhanced PARP-1 cleavage and increased levels of p53 in those
cells that become irreversible committed to cell death [88].
Considering that PARP-1 is thought to be an important modulator of p53 [89], either by co‐
valent modification or by non-covalent binding of poly(ADP-ribose) on specific domains of
p53, which alter its DNA binding functions [47], the binding of p53 to DNA damage pro‐
motes activation of downstream signal cascades, leading to cell cycle arrest and apoptosis. A
recent report have demonstrated the efficacy of a novel CDK1, CDK2 inhibitor, dansylated
VMY-1-103, in inhibiting Erb-2/Erb-3/heregulin-induced cell proliferation in LNCaP cells.
Apoptosis via decreased mitochondrial membrane polarity, induction of p53 phosphoryla‐
tion, caspase-3 activation, and PARP-1 cleavage in these prostatic tumor cells, were also
among the most relevant findings [90]. The stability of p53 as evidenced by an increase of
p53 content is crucial for blocking cell cycle progression or for initiating cell death apoptosis
in response to DNA damage [91, 92]. However, it cannot be excluded that other DNA repair
proteins can also bind simultaneously to the damaged site and may activate alternative sig‐
naling pathways in response to genotoxic insults. The determinant of which of these mecha‐
nisms is chosen can be dependent on the magnitude of damage to the DNA.
Although p53 and PARP-1 are both damage sensor proteins and can be functionally activat‐
ed by DNA damage [92, 93], evidence indicated that PARP-1 is not essential for p53 accu‐
mulation induced by DNA damage. However, PARP-1 appear to be required for the
appropriate response of p53 to DNA damage [89], including its rapid and enhanced protein
expression [91]. In this respect, immunoblotting analysis with antibodies against p53 were
able to detect p53 protein in lysates of PARP-1 wild-type cells, but not in PARP-1 deficient
cell extracts, which suggested that the reduced protein stability of p53 in cells lacking
PARP-1 [94]. The functional interaction between p53 and PARP-1 in response to radiation
was also reported in a human glioblastoma cell line A-17 treated with 3-aminobenzamide (3-
AB), a well-known PARP-1 inhibitor. The absence of PARP-1 activity by 3-AB dramatically
reduced the radiation-induced expression of the p53 downstream, the p21 gene product. In
support to this observation, the gel shift analysis evidenced that 3-AB significantly inhibited
the irradiation-activated p53-binding activity to its consensus sequences [95]. Similar results
were observed in a (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (MPTP)-induced parkin‐
sonism model in which a heavy poly(ADP-ribosyla)tion modification of p53 reduced the
DNA-binding activity of p53 to its consensus sequences [96].
Although the specific findings above described clearly proof that PARP-1 expression is im‐
plicated in p53 accumulation and stabilization, this effect is different to that observed in
PARP-1 knock out cells exposed to N-methyl-N-nitroso urea (MNU), an alkylating agent, in
which p53 is accumulated and its activation is consistently enhanced [97]. The findings in
this model suggest that PARP-1 regulating p53-mediated response to genotoxic agents is
probably dependent on the type of DNA damage. Accordingly the level of MDM-2 tran‐
script, an important negative regulator of the p53, was not increased after gamma-irradia‐
tion; however, an increased in the expression of MDM-2 protein was observed in PARP-1
null cells. The increased levels of MDM-2 may provide an alternative explanation for the re‐
duced accumulation and activation of p53 in PARP-1 null cells. Furthermore, the reduced
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phosphorylation of p53 may also be indicative of a defective activation of the kinases path‐
ways in these cells [97].
Other studies have demonstrated that PARP-1 is dispensable for the repair of DNA double-
strand breaks induced by alkylating agents, UV, and gamma-radiation. In this respect, it
was proposed the existence of an alternative radiation-induced pathway involving p53 that
may function independently of PARP-1 involvement. Although this alternative mechanism
may explain the cytotoxic response detected in PARP-1 null cells after radiation treatment
[61, 98], this does not necessarily support the significant delay in the transient accumulation
of p53 in PARP-1-depleted intestinal epithelial stem cells after exposure to irradiation. Simi‐
larly, the survival analysis was markedly reduced in crypts of PARP-1 knockout mice, even
at radiation doses that have sublethal effects on wild type animals [65]. These observations
extended the crucial role of PARP-1 to stem cells survival after DNA damage in vivo. Indeed,
considering the prolonged regenerative capacity of prostate progenitor stem cells may in‐
crease their susceptibility to accumulate genetic or epigenetic alterations during their life cy‐
cle, the events may be able to increased proliferative rates, decreased cell death, and overall
survival advantages over prostate progenitor stem cells, contributing thus to transformation
[6, 99-104]. Along with these studies, PARP-1 inhibition may be a critical component in the
treatment of some types of cancer. Additionally, other components of the cell cycle check‐
points such p53 also need to be considered in order to develop an appropriate therapy strat‐
egy to avoid relapse.
5. The prostate cancer microenvironment
The morphology of a tumor may also influence in the biological responses of cancer cells to
a specific therapy. Although most of the reports in cancer therapy utilize monolayer cul‐
tures, multicellular aggregates (spheres) are probably more important because reflects the
three-dimensional structure for a real-time model representing a tumor, allowing to study
the interaction of tumor cells with the microenvironment [105]. The fact that spheroids mim‐
ic the tumor microenvironment is also an important tool that may provide more accurate in‐
formation about the biological and biochemical events occurring in solid tumors [106].
Therefore, the utilization of the spheres assay is an important approach for the in serial in
vivo transplantation to verify self-renewal potential.
Although, sphere cells are generated, serially passaged, and maintained in undifferentiated
phenotype under appropriate cell culture conditions, they need to be inoculated into animal
models to confirm their ability to generate tumor growth [107, 108]. Indeed, substantial dif‐
ferences has been reported in the gene expression signatures on PC3 holoclones compared
to parental PC3 cells, which appeared to be consequence of the distinct culture conditions
used to growth each cell population [109]. Consistent with these observations, growing con‐
ditions also affected the expression of several genes in LNCaP cells [106]. A number of other
variables such as the manner in which cells are isolated and the in vitro propagation of these
cells before transplantation can cause tumor cells to become more aggressive as a result of
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new acquired mutations, which may affect the outcome of in vivo assays. Another critical pa‐
rameters are to determine the variation on experimental conditions that may influence fre‐
quency estimates and to ensure the best animal model available in order to reproduce the
tumor biology as it occurs in humans. For example, the limiting dilution data might be dra‐
matically affected by the duration of data analysis [110] or by modification of xenotrans‐
plantation assay in non-obese diabetic severe combined immunodeficient (NOD/SCID) mice
[111]. Therefore, a main concern for the application of this methodology is that sometimes,
the animal models overstate the biology of cancer formation in humans.
Most of human prostate tumor cells have the ability to form spheres; however, the frequen‐
cy of cells forming spheres is very heterogeneous across all cell lines. In this regard, the
adaptation of tumor cells to non-adherent culture conditions may be a determinant in form‐
ing spheres [112]. Also, the holoclone-forming cells, which are smaller than paraclone cells,
more adherent, highly clonogenic, and whose progeny forms almost exclusively growing
colonies, in prostate cancer specimens with the highest clonogenic potential has been associ‐
ated with stem cell phenotypes [113]. Of great importance is the fact that large holoclones
were also consistently present in prostate cancer cell spheres [109, 114], suggesting that
these spheres, which are sustained by tumor initiating cells with stem cell-like features, may
have a strong self-renewal and pro-angiogenic capability [115]. These spheres were capable
of forming new generations of spheres and retained proliferative capacity as well as clono‐
genic potential after serial passages [116]. These reports were supported by studies in which
a minor subpopulation of spheres propagating cells with stem cell-like properties isolated
from a series of prostate cancer models were capable of forming spheres, display significant
increase in proliferation potential, initiate xenograft tumors with enhanced capacity, and
were more drug resistant compared to monolayer cells [109, 117]. Accordingly, the expres‐
sion of putative cancer stem cell markers such as ALDH1A1, CD44, CD133, showed strong
correlation with prostate tumor progression and metastasis [92, 118, 119], while Nanog in‐
duction promoted castration-resistant tumor phenotype and tumor regeneration in the
LNCaP cells [120].
There is no doubt that the microenvironment definitely affects the expression of multiples
genes that may be more evident in spheroids in which the tumor cell interaction with the
extracellular matrix may influence responses to prostate cancer treatment. Thus, the three-
dimensional system should be included in pre-clinical experimental models to identify in
prostate tumors the mechanisms that are related with tumor progression, and those that
confer resistant to cancer therapies.
6. Treating prostate cancer
Despite recent therapeutic approaches that have significantly increased survival, most pros‐
tate aggressive tumors become resistant to current treatment protocols [8, 121]. Prostate can‐
cers that initially respond to standard chemotherapy often recur with selective outgrowth of
tumor cell subpopulations that are resistant not only to the original chemotherapeutic
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agents, but also to other therapeutics [122]. Several events are thought to be involved in the
dysregulation of pathways, which may activate a different pathway(s) for androgen inde‐
pendence probably through a paracrine androgen-independent pathway, which may ex‐
plain the multifocality and heterogeneity of prostate cancer and for hormone therapy
resistance. Indeed, in a xenograft model, most of androgen-responsive genes that were ini‐
tially downregulated under conditions of androgen deprivation were later re-expressed in
recurrence tumors, indicating failure of androgen-derivation therapy as well as irreversible
commitment to tumor progression [123].
The array of genes that comprise the proliferation status may differ in different type of tu‐
mors. Evidence has demonstrated that the cell cycle regulation is frequently altered in pros‐
tate cancers, in part, by the interplay of oncogenic cascades activation with diverse
hormones, growth factors, and cytokines. Moreover, the accumulation of mutations in pros‐
tate cancer cells may eventually lead to a more poorly differentiated and aggressive tumor
behavior, leading to overall higher rates of progression and worse prognosis, irrespective of
the size of the lesion [124-127]. Multiple cellular signaling pathways including, protein kin‐
ase B (Akt), mitogen-activated protein kinase (MAPK), the nuclear factor kappa B (NF-κB),
transforming growth factor beta (TGF-β), the vascular endothelial growth factor (VEGF),
and the Wnt have been shown to enhance androgen receptor signaling and promote devel‐
opment of hormone-independent/castration-resistance in preclinical models [128, 129].
Moreover, the increased expression of the androgen receptor transcript was critical for tu‐
mor cells resistance to anti-androgen therapy [75]. In this regard, inhibitors of cell cycle reg‐
ulatory proteins has become an area of increased interest in targeting both cancer cells per se
and a subpopulation of stem cell-like that initiates and maintains tumor growth, metastasis,
and resistance to therapy [130].
Recently, we have demonstrated that Phenoxodiol induces DNA damage in different types
of prostate cancer cell lines (DU145, LNCaP, and PC3), leading to the activation and cleav‐
age of PARP-1 as well as the onset of the cell death program [72]. Interesting, the expression
of PARP-1 is highly expressed in LNCaP cells before and after treatment with H2O2 [131].
Also accompanying Phenoxodiol-induced cell death we observed a reduction in the availa‐
bility of NAD+, which potentially compromises ATP production via glycolysis [132]. A ma‐
jor component of the injury is the alteration of membrane permeability caused by decreased
activity of ATP-dependent ionic pumps [133]. Massive NAD+ depletion is lethal in cells that
divide rapidly and have a high-energy requirement. Since the three prostate cancer cell
lines, LNCaP, PC3, and DU145 have high metastatic potential and are very resistance to sev‐
eral antitumoral drugs and radiation-induced apoptosis, the fact that this synthetic analogue
of Genistein induces death in this tumor type, strongly suggested that this synthetic drug
may be a useful treatment for metastatic prostate tumors [72]. A recent study has reported
that decreased PSA production and the expression of the androgen receptor in LNCaP cells
were observed following a combined treatment with curcumin and isoflavones. Similarly,
modulation of PSA levels was observed in a cohort of patients that received prostate biop‐
sies [134]. Finally, cannabidol and the synthetic cannabinoid WIN-55,212 were also determi‐
nant in inhibit proliferation and cleavage of PARP-1, caspase-3, as well as activation of
The Role of PARP Activation in Prostate Cancer
http://dx.doi.org/10.5772/53297
601
phosphatases, and pro-apoptotic phosphatase on LNCaP cells. These compounds also exhib‐
ited antitumorigenic activity against different types of tumors and are now being tested in
clinical trials for the treatment of brain tumors [135, 136]. The modulation of specific phos‐
phatases in the LNCaP cell line suggested the potential antitumorigenic activity of cannabi‐
noids against the treatment of prostate cancers [137].
7. Treating prostate cancer with PARP-1 inhibitors
Recently,  the augmented immunodetection of PARP-1 was associated with prostate can‐
cer progression and prediction of biochemical recurrence [138]. Preclinical data also indi‐
cated  that  PARP  inhibitors  might  sensitize  cancer  cells  and  potentiate  the  effects  of
radiotherapy and chemotherapy.  Interesting,  inhibition  or  depletion  of  PARP-1  by  anti‐
sense RNA [139],  chemical  inhibitors  [140-142],  or  by the  expression of  dominant  nega‐
tive  mutants  (4-5),  promotes  genomic  instability  [143],  as  revealed  by  increased  DNA
strand  breakage,  gene  amplification,  micronuclei  formation,  and  sister  chromatide  ex‐
changes (SCE) in cells exposed to genotoxic agents. Marked SCE frequency has been ob‐
served in PARP-1 deficient cell lines and treated with different inhibitors against PARP-1
activity [144]. Depletion of PARP-1 was indicated as the main contribution to genomic al‐
terations that may promote aberrant expression of cell proliferative genes, which may ini‐
tiate cancer formation or progression. These observations implicate PARP-1 as a guardian
of  the  genome,  facilitating  DNA  repair  and  protection  against  DNA  recombination  by
DNA  lesion  recognition  [144]  Accordingly,  nuclear  PARP-1  protein  overexpression  was
associated with poor overall  survival  in early breast  cancer  [145].  PARP inhibitors  have
also  been implicated in  the  modulation of  the  mechanisms driving apoptotic  cell  death
[146].  Therefore,  evidence correlating increased PARP-1 activity  with  tumor progression
has opened a new avenue for the utilization of  PARP inhibitors,  which may impair the
DNA  repair  machine.  These  effects  may  increase  sensitivity  of  prostate  tumor  cells  to
DNA damaging agents by improving the efficiency of cancer therapeutics.
An early innovative therapy to treat prostate cancer cells was to enforce the binding of DNA
strand breaks to a dominant-negative mutant of the DNA-binding domain of PARP. The re‐
combinant plasmid inhibited the function of PARP-1 and sensitized prostate tumor cells to
the lethal effects of ionizing radiation or etoposide (VP-16), with a markedly reduction of
cell survival and induction of apoptosis [12]. The pharmacological inhibition of PARP-1 by
benzamide pharmacaphores mimics the nicotinamide moiety of NAD+, occupying the donor
site [147]. For example, the 3-aminobenzamide (3-AB) was shown to inhibit DNA excision
repair and radiosensitize cells to ionizing radiation through impaired DNA repair [148, 149].
3-AB is also know to inhibit the family of mono(ADP-ribose) transferases, which can pro‐
duce non-specific effects independent of PARP-1 inhibition (Milam, 1984). Therefore, more
potent and highly specific PARP inhibitors that promote oxid radiation sensitizer enhance‐
ment ratios have been developed. These new specific compounds (Table 4) are dependent of
the cell line and inhibitor tested [150]. Thus, for example ABT-888 (veliparib) inhibited re‐
combinant and intracellular PARP-1 activity and was also toxic to both oxic and hypoxic
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cells. This PARP inhibitor radiosensitize the human prostate carcinoma cell lines DU145 and
22RV1, as evidenced by the reduced clonogenic survival followed by ionizing radiation ex‐
posure (Stanley, 2008). Further support for the utilization of ABT-888 in combination thera‐
py comes from studies showing that ABT-888 enhanced the effects of ionizing radiation in
DU145 and PC-3 cells [151]. Interestingly, only PC-3 cells undergo enlarged flat morphology
and positive staining for SA-β-Gal, and significant overexpression of p21, hallmarks of cell
senescence. These findings were confirmed using PC-3 tumor xenografts in which tumor
growth was delayed and presented a senescent phenotype. These results appear to indicate
that combined ionizing radiation and PARP inhibition may improve therapeutic response in
specific types of prostate cancer.
Function Acceptor proteins
ABT888 (Veliparib) Enhances cell death and tumor growth delay in irradiated cancer
models
5-AIQ hydrochloride Decreases expression of inflammatory mediators activated by
neutrophils
3-Methil-5-AIQ hydrochloride l Therapeutic benefits on myocardial infarction, ischaemia-reperfusion
of the liver and kidney, heart transplantation, and acute lung
inflammation
3-Aminobenzamide Potentiate anticancer therapy
4-Amino-1,8-naphthalimide Radiation sensitizer
Benzamide Neuroprotectant
3-(4-Chlorophenyl)quinoxaline-5-carboxamide Ameliorates methamphetamine-induced dopaminergic
neurotoxicity
(3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-
isoquinolinone DPQ
Reduces pre-neoplastic foci, expression of pre-neoplastic markers,
and pro-inflammatory genes in hepatocarcinomas
DR2313 Neuroprotectan
EB-47.dihydrochloride.dihydrate Antioxidant
4-Hydroxyquinazoline Antioxidant
5-Iodo-6-amino-1,2-benzopyrone Neuroprotectan
1,5-Isoquinolinediol Reduces repair of DNA damaged
Minocycline hydrocloride Anti-inflammatory and neuroprotectan
Nicotinamide Chemo- and radio-sensitizer
NU1025 Neuroprotectant
6(5H)-Phenanthridinone Immunosuppressant
PJ-34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-
N, N-dimethylacetamide.HCl]
Anti-inflammatory
TIQ-A Neuroprotectant
Table 4. A panel of PARP inhibitors
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The clinical experiences with PARP inhibitors are now focus on patients carrying mutations
of the BRCA1 or BRCA2 genes, which have been linked to increased sensitivity to PARP-1
inhibitors. For example Olaparib has proved to be very efficient in patients with breast or
ovarian cancer with germline mutations in these two genes [152-154]. Although mutations
on BCRA2 mutations have a major impact on breast cancer growth, males carrying altera‐
tion on this gene also have a high risk of develop prostate cancer [153, 155]. Additional evi‐
dence has shown that impaired DNA repair might benefit from treatment with PARP
inhibitors. In deed several evidences have proved that PARP inhibitors sensitize human
prostate cancer cell lines [148, 149, 156]. It is also know that treatment with high doses of
chemotherapy induces massive DNA damage leading to PARP-1 overactivation with the
subsequent energy depletion and cell death of tumor cells that are highly resistant [157].
More recently, it was described that PARP-1 mediates the oncogenic EST transcription factor
ERG, which is frequently observed in fusion to the androgen-regulated gene TMPRSS2 in a
significant amount of prostate tumors [158]. PARP-1 inhibition (treatment with Olaparib) in
this group of tumors increases expression of the ETS gene, which promotes accumulation of
DNA damage. This study also demonstrated that ERG physically interacts with PARP-1 and
DNA-PKCsPARP-1 and that PARP-1 has a critical role on ERG-mediated transition from
high-grade prostatic intraepithelial neoplasia to invasive carcinoma [159]. These findings
clearly showed that PARP-1 inhibition could potentially increase survival of patients with
tumors ETS-positive. Interesting, Olaparib remained ineffective on tumors that did not show
the gene fusion. Altogether this evidence support the enormous interest in stimulate the uti‐
lization of a new generation of relatively non-toxic, orally administered PARP inhibitors in a
series of cancer in clinical trials to induce genomic instability and cell death, blocking the
grow and spread of cancer cells. The fact that PARP inhibition is specific against prostate
cancer cells is an exciting and promising therapy approach, in part, because they may cause
less severe effects than traditional therapies or radiotherapy.
8. Conclusion
This review has highlighted the therapeutic potential of PARP inhibitors in prostate cancer
as a monotherapy or in combination with another type therapy. PARP-1 is implicated in sta‐
bilizing the genomic content as well as in the selection of cells with unrepaired DNA dam‐
aged. A large body of evidence has demonstrated that inhibition of PARP-1 was sufficient to
promote the development of tetraploidy in normal cells and effectively enhanced DNA
damage in response to genotoxic agents. These results proved that the physical disruption of
PARP-1 is essential for the maintenance of genomic instability. The increased expression of
PARP-1 in a series of tumors has been related with cell proliferation and determination of
the biological behavior of tumors, events that may predict the overall prognosis of the can‐
cer. In this regard, studies on prostate cancer models in vitro and in vivo have shown that
PARP inhibitions regulated the growth of tumors or prevented tumor invasion to other or‐
gans. Although several studies have provided promising results in treating advanced tu‐
mors, few clinical trials are available in prostate cancer, one of the most prevalent cancers
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affecting men. Indeed, PARP inhibitors are currently tested in breast cancer patients with
mutations in the BRCA1 and BRCA2, which are also mutated in a significant number of
prostate cancers. Since advanced prostate cancer generally develops resistance to chemo‐
therapeutic and hormone therapies, the identification of mechanisms underlying prostate
cancer progression is vital to identify potential targets for prostate cancer therapy. Recent
findings have demonstrated that BRCA1 and BRCA2 mutations confer sensitivity to PARP
inhibitors, promoting genomic instability and cell death, and that tumors with BRCA1 mu‐
tated are potential targets for a new generation of non-toxic PARP inhibitors. Moreover, the
mechanism by which PARP-1 inhibition and BRCA mutations allow the accumulation of
DNA errors and the promotion of tumor growth in prostate cells may provide the basis to
develop more effective strategies for therapeutic intervention. However, the identification of
new genetic markers are necessary to define the feasibility of PARP-1 as a therapeutically
target for the treatment of patients with prostate cancer.
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